NASDAQ:TLIS Talis Biomedical (TLIS) Stock Price, News & Analysis $1.72 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Talis Biomedical Stock (NASDAQ:TLIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Talis Biomedical alerts:Sign Up Key Stats Today's Range$1.72▼$1.7250-Day Range$1.37▼$4.3852-Week Range$1.37▼$9.60Volume32 shsAverage Volume4,755 shsMarket Capitalization$3.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTalis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive TLIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address TLIS Stock News HeadlinesTalis Biomedical (NASDAQ:TLIS) Stock Price Down 1.7% - Here's What HappenedNovember 2 at 3:21 AM | americanbankingnews.comBaker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical CorpOctober 11, 2024 | finance.yahoo.comTrue paradigm shiftI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. November 2, 2024 | Porter & Company (Ad)Talis Biomedical Corp Ordinary SharesSeptember 17, 2024 | morningstar.comTalis Biomedical Shares Fall on Bankruptcy Filing, Delisting NoticeAugust 24, 2024 | marketwatch.comTLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024August 20, 2024 | investorplace.comTalis Biomedical Shares Tumble Premarket as Company Mulls BankruptcyAugust 7, 2024 | marketwatch.comWhy Talis Biomedical (TLIS) Stock Is Getting Obliterated TodayAugust 7, 2024 | benzinga.comSee More Headlines TLIS Stock Analysis - Frequently Asked Questions How have TLIS shares performed this year? Talis Biomedical's stock was trading at $7.45 at the beginning of the year. Since then, TLIS stock has decreased by 76.9% and is now trading at $1.72. View the best growth stocks for 2024 here. How were Talis Biomedical's earnings last quarter? Talis Biomedical Co. (NASDAQ:TLIS) issued its quarterly earnings results on Monday, August, 19th. The company reported ($4.86) earnings per share (EPS) for the quarter. Talis Biomedical had a negative trailing twelve-month return on equity of 79.74% and a negative net margin of 5,784.73%. When did Talis Biomedical's stock split? Shares of Talis Biomedical reverse split on the morning of Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Talis Biomedical IPO? Talis Biomedical (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Talis Biomedical? Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Talis Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM). Company Calendar Last Earnings8/19/2024Today11/02/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TLIS CUSIPN/A CIK1584751 Webtalis.bio Phone650-433-3000FaxN/AEmployees260Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($28.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,010,000.00 Net Margins-5,784.73% Pretax Margin-12,506.37% Return on Equity-79.74% Return on Assets-57.16% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$2.13 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value$37.95 per share Price / Book0.05Miscellaneous Outstanding Shares1,820,000Free Float984,000Market Cap$3.13 million OptionableNo Data Beta1.56 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:TLIS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talis Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.